Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults : a population-based cohort study
© The Author(s) 2024. Published by Oxford University Press on behalf of the International Epidemiological Association..
BACKGROUND: Recommendations around the use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) seldom focus on potential benefits of vaccine on comorbidities. We aimed to investigate whether sequential vaccination with PCV13 and PPSV23 among older adults would provide protection against cardiovascular diseases (CVD) compared with using a single pneumococcal vaccine.
METHODS: We conducted a Hong Kong-wide retrospective cohort study between 2012 and 2020. Adults aged ≥65 years were identified as receiving either a single or sequential dual vaccination and followed up until the earliest CVD occurrence, death or study end. To minimize confounding, we matched each person receiving a single vaccination to a person receiving sequential vaccination according to their propensity scores. We estimated the hazard ratio (HR) of CVD risk using Cox regression and applied structural equation modelling to test whether the effect of sequential dual vaccination on CVD was mediated via the reduction in pneumonia.
RESULTS: After matching, 69 390 people remained in each group and the median (interquartile range) follow-up time was 1.89 (1.55) years. Compared with those receiving a single vaccine, those receiving sequential dual vaccination had a lower risk of CVD [HR (95% CI): 0.75 (0.71, 0.80), P < 0.001]. Post-hoc mediation analysis showed strong evidence that the decreased CVD risk was mediated by the reduction in all-cause pneumonia.
CONCLUSIONS: Sequential dual pneumococcal vaccination was associated with lower risk of CVD compared with single-dose PCV13 or PPSV23 in older adults. Such additional CVD benefits should be considered when making decisions about pneumococcal vaccination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
International journal of epidemiology - 53(2024), 1 vom: 01. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tong, Xinning [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cardiovascular diseases |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/ije/dyae005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36822063X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36822063X | ||
| 003 | DE-627 | ||
| 005 | 20240214233256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ije/dyae005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM36822063X | ||
| 035 | |a (NLM)38332579 | ||
| 035 | |a (PII)dyae005 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tong, Xinning |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of sequential vs single pneumococcal vaccination on cardiovascular diseases among older adults |b a population-based cohort study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the International Epidemiological Association. | ||
| 520 | |a BACKGROUND: Recommendations around the use of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13) seldom focus on potential benefits of vaccine on comorbidities. We aimed to investigate whether sequential vaccination with PCV13 and PPSV23 among older adults would provide protection against cardiovascular diseases (CVD) compared with using a single pneumococcal vaccine | ||
| 520 | |a METHODS: We conducted a Hong Kong-wide retrospective cohort study between 2012 and 2020. Adults aged ≥65 years were identified as receiving either a single or sequential dual vaccination and followed up until the earliest CVD occurrence, death or study end. To minimize confounding, we matched each person receiving a single vaccination to a person receiving sequential vaccination according to their propensity scores. We estimated the hazard ratio (HR) of CVD risk using Cox regression and applied structural equation modelling to test whether the effect of sequential dual vaccination on CVD was mediated via the reduction in pneumonia | ||
| 520 | |a RESULTS: After matching, 69 390 people remained in each group and the median (interquartile range) follow-up time was 1.89 (1.55) years. Compared with those receiving a single vaccine, those receiving sequential dual vaccination had a lower risk of CVD [HR (95% CI): 0.75 (0.71, 0.80), P < 0.001]. Post-hoc mediation analysis showed strong evidence that the decreased CVD risk was mediated by the reduction in all-cause pneumonia | ||
| 520 | |a CONCLUSIONS: Sequential dual pneumococcal vaccination was associated with lower risk of CVD compared with single-dose PCV13 or PPSV23 in older adults. Such additional CVD benefits should be considered when making decisions about pneumococcal vaccination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PCV13 | |
| 650 | 4 | |a PPSV23 | |
| 650 | 4 | |a Pneumococcal vaccine | |
| 650 | 4 | |a cardiovascular diseases | |
| 650 | 4 | |a older adults | |
| 650 | 7 | |a Vaccines, Conjugate |2 NLM | |
| 650 | 7 | |a Pneumococcal Vaccines |2 NLM | |
| 700 | 1 | |a Gao, Le |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Ian C K |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Vivien K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Angel Y S |e verfasserin |4 aut | |
| 700 | 1 | |a Mak, Judith C W |e verfasserin |4 aut | |
| 700 | 1 | |a Yuen, Jacqueline K Y |e verfasserin |4 aut | |
| 700 | 1 | |a Jit, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Ivan F N |e verfasserin |4 aut | |
| 700 | 1 | |a Yiu, Kai Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xue |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of epidemiology |d 1975 |g 53(2024), 1 vom: 01. Feb. |w (DE-627)NLM00011930X |x 1464-3685 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2024 |g number:1 |g day:01 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ije/dyae005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2024 |e 1 |b 01 |c 02 | ||